CTIS2023-506241-30-00进行中（未招募）1 期
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy - 849-010
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 561
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically confirmed diagnosis of colorectal carcinoma G12C mutation in tumor tissue., Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.
排除标准
- •Prior treatment with both an oxaliplatin-and irinotecan-based regimen for CRC, concurrently or successively, in any setting (neoadjuvant, adjuvant or advanced)., Prior treatment with a therapy targeting KRAS G12C mutation (e.g., sotorasib)., Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).
研究者
相似试验
进行中（未招募）
1 期
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C MutatioEUCTR2020-004048-27-CZMirati Therapeutics, Inc.420
进行中（未招募）
1 期
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C MutatioAdvanced Colorectal Cancer with KRAS G12C MutationMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004048-27-FIMirati Therapeutics, Inc.420
进行中（未招募）
1 期
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C MutatioEUCTR2020-004048-27-ATMirati Therapeutics, Inc.420
进行中（未招募）
1 期
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C MutatioAdvanced Colorectal Cancer with KRAS G12C MutationMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004048-27-DEMirati Therapeutics, Inc.420
进行中（未招募）
1 期
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C MutatioAdvanced Colorectal Cancer with KRAS G12C MutationMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004048-27-PTMirati Therapeutics, Inc.420